Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score

Tendas, Andrea; Sollazzo, Fabio; Niscola, Pasquale; Cupelli, Luca; Mauroni, Maria Rita; D’Apolito, Antonella; Pilozzi, Vittoria; Cacciaraichi, Stella; Viggiani, Caterina; Annibali, Ombretta; Mengarelli, Andrea; Dentamaro, Teresa; Fabritiis, Paolo de; Arcese, William

doi:10.1007/s00520-012-1550-4

Cited by 6 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there are some differences between the various antiemetic guidelines, they all provide evidence-based reasonably consistent recommendations to guide clinicians on the optimal use of antiemetics. Unfortunately, barriers exist which continue to interfere with administration of guideline-based antiemetic prophylaxis [ 6 – 9 , 20 – 22 ], despite compelling research indicating that nonadherence leads to diminished CINV control for patients [ 6 , 7 ]. In the large studies by Aapro and Gilmore [ 6 , 7 ], it was discouraging that the patients at highest risk for CINV (i.e., those receiving HEC or AC chemotherapy) were the ones where the incidence of guideline inconsistent prophylaxis was highest.…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, despite substantial research supporting the fact that guideline conformity will improve CINV control for patients, adherence to antiemetic guidelines is inadequate [ 6 – 9 ]. With the goal of improving the quality of care and quality of life for cancer patients undergoing emetogenic chemotherapy treatment, the Multinational Association of Supportive Care in Cancer (MASCC), in particular, continues to strive to educate clinicians on the importance and value of appropriate antiemetic prophylaxis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Hesketh

Aapro

Jordan

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Combination antiemetic regimens targeting multiple molecular pathways associated with emesis have become the standard of care for prevention of chemotherapy-induced nausea and vomiting (CINV) related to highly and moderately emetogenic chemotherapies. Antiemetic consensus guidelines from several professional societies are widely available and updated regularly as new data emerges. Unfortunately, despite substantial research supporting the notion that guideline conformity improves CINV control, adherence to antiemetic guidelines is unsatisfactory. While studies are needed to identify specific barriers to guideline use and explore measures to enhance adherence, a novel approach has been taken to improve clinician adherence and patient compliance, with the development of a new combination antiemetic. NEPA is an oral fixed combination of a new highly selective NK1 receptor antagonist (RA), netupitant, and the pharmacologically and clinically distinct 5-HT3 RA, palonosetron. This convenient antiemetic combination offers guideline-consistent prophylaxis by targeting two critical pathways associated with CINV in a single oral dose administered only once per cycle. This paper will review and discuss the NEPA data in the context of how this first combination antiemetic may overcome some of the barriers interfering with adherence to antiemetic guidelines, enhance patient compliance, and offer a possible advance in the prevention of CINV for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Hesketh

Aapro

Jordan

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Tendes and colleagues [32] recommend that a CINV reduction score based on the actual antiemetic dose ordered may better evaluate guideline prescribing. We found that computerized standardized order-sets containing the accurate antiemetic dose and frequency are an effective method both to prevent guideline antiemetic under/overdosing and reduce acute/delayed CINV.…”

Section: Discussionmentioning

confidence: 99%

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice

Affronti

Schneider

Herndon

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

Purpose A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately-emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting (CINV) reduce cancer treatment efficacy and significantly impair cancer patients’ quality of life (QOL). Review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)’s usual practice demonstrates a high incidence (45%) of CINV, despite premedication with short-acting 5-HT3-serotonin receptor antagonists (5-HT3-RAs). National Comprehensive Cancer Network (NCCN)’s evidence-based guidelines recommend the combination of the long-acting 5-HT3-RA palonosetron (PAL) and dexamethasone (DEX) for the prevention of acute and delayed CINV with MEC. Low adherence (58%) to antiemetic guidelines may have explained our high CINV incidence. Methods One-sample, quasi-experimental design evaluated a combination intervention that included a provider education session; implementation of risk-assessment tool with computerized, standardized antiemetic guideline order-sets; and a monthly audit-feedback strategy. Post-implementation adherence to evidence-based antiemetic order-sets and patient outcomes were measured and compared to baseline and historical data. Primary outcome was the guideline order-set adherence rate. Secondary outcomes included nausea/vomiting rates and QOL. Results Adherence to ordering MEC guideline antiemetics increased significantly, from 58% to a sustained 90%, with associated improvement in nausea/vomiting. In acute and delayed phases, 75% and 84% of patients, respectively, did not experience CINV. There was no significant change in QOL. Conclusion Combination intervention and audit-feedback strategy to translate evidence into oncology practice improved and sustained adherence to antiemetic guidelines. Adherence corresponded with effective nausea/vomiting control and preserved QOL in patients with malignant gliomas.

show abstract

Bone marrow aspiration and biopsy-related pain management

et al. 2013

View full text Add to dashboard Cite

Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score

Cited by 6 publications

References 4 publications

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice

Bone marrow aspiration and biopsy-related pain management

Contact Info

Product

Resources

About